Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the second of four virtual R&D event...
ILT2, ILT4, ILT3 and LAIR1 are myeloid checkpoints that may play a central role in establishing an immune-suppressive state in the tumor microenvironment NGM707, NGM831 and NGM438 are all engineered to release myeloid checkpoints and reprogram myeloid cells to reverse immune suppres...
After two straight sessions of losses, the shares of NGM Biopharmaceuticals (NASDAQ:NGM +14.6%) have recorded the biggest ever intraday gain after the clinical-stage biotech announced the dosing of the first patient in its early-stage trial for the tumor candidate, NGM831. With the Phase...
Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA ® (pembrolizumab) initiated and expected to enroll up to approximately 80 patients NGM831 is the second ...
--The four-part series titled the “Explorer Series” will showcase NGM Bio’s discovery engine, myeloid reprogramming and checkpoint inhibition portfolio and program for the treatment of geographic atrophy-- SOUTH SAN FRANCISCO, Calif., March 21, 2022 (G...
Over 10 million people are stricken by cancer each year, with as much as 60% suffering from loss of appetite or anorexia and wasting disease or cachexia. With no standard of care available to treat patients with cancer-related anorexia, there is an eager patient population ready for a...
Oral presentation to showcase NGM Bio’s in vitro and in vivo research demonstrating potential advantages of dual ILT2/ILT4 inhibition with NGM707, currently in Phase 1/2 trial Late-breaking poster presentations to highlight preclinical research supporting development of...
NGM Biopharmaceuticals press release (NASDAQ:NGM): Q4 GAAP EPS of -$0.35 beats by $0.01. Revenue of $20.96M (+6.0% Y/Y) beats by $0.76M. For further details see: NGM Biopharmaceuticals GAAP EPS of -$0.35 beats by $0.01, revenue of $20.96M beats by $0.76M
Advanced programs across NGM Bio’s pipeline in retinal diseases, oncology and liver and metabolic diseases during the fourth quarter and beginning of 2022: Obtained Fast Track designation from the U.S. Food and Drug Administration (FDA) for NGM621, an anti-complement C3 antibod...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Office...
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...